Statements (103)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Karyopharm_Therapeutics
gptkb:Karyopharm_Therapeutics_Inc. |
| gptkbp:activities |
inhibits nuclear export
exportin 1 inhibitor |
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:2019
gptkb:FDA |
| gptkbp:brand |
Xpovio
|
| gptkbp:can_be_used_with |
gptkb:bortezomib
gptkb:lenalidomide gptkb:dexamethasone |
| gptkbp:class |
selective inhibitor
|
| gptkbp:clinical_trial |
gptkb:healthcare_organization
gptkb:relapsed_or_refractory_multiple_myeloma variable Phase 1 combination therapy Phase 2 Phase 3 improved overall survival diffuse large B-cell lymphoma monotherapy reduced tumor size relapsed or refractory DLBCL |
| gptkbp:contraindication |
hypersensitivity
severe liver impairment severe hepatic impairment hypersensitivity to selinexor |
| gptkbp:developed_by |
gptkb:Karyopharm_Therapeutics
|
| gptkbp:discovered_by |
2010s
|
| gptkbp:dosage_form |
gptkb:tablet
60 mg weekly |
| gptkbp:duration |
until disease progression
|
| gptkbp:effective_date |
July 2019
|
| gptkbp:ends_at |
combination with other agents
|
| gptkbp:excretion |
urine
feces |
| gptkbp:frequency |
once weekly
twice weekly |
| gptkbp:government_type |
New Drug Application (NDA)
|
| gptkbp:healthcare |
July 2019
tablet form |
| https://www.w3.org/2000/01/rdf-schema#label |
Selinexor
|
| gptkbp:indication |
gptkb:healthcare_organization
diffuse large B-cell lymphoma |
| gptkbp:ingredients |
C19 H20 Cl N3 O3 S
selinexor C20 H22 Cl N3 O3 S |
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors |
| gptkbp:invention |
gptkb:Karyopharm_Therapeutics
patented |
| gptkbp:is_atype_of |
L01 X X55
|
| gptkbp:is_effective_against |
demonstrated in trials
|
| gptkbp:is_monitored_by |
electrolytes
liver function tests complete blood count renal function tests blood counts |
| gptkbp:is_used_for |
gptkb:healthcare_organization
|
| gptkbp:lifespan |
approximately 6 hours
|
| gptkbp:manager |
oral
|
| gptkbp:market |
August 2019
|
| gptkbp:marketed_as |
Xpovio
|
| gptkbp:metabolism |
liver
|
| gptkbp:operational_status |
approved
|
| gptkbp:pharmacokinetics |
oral bioavailability
bioavailability 20% to 30% half Life 6 to 10 hours inhibits nuclear export |
| gptkbp:population |
adults
elderly relapsed or refractory patients |
| gptkbp:provides_information_on |
ASCO guidelines
included in treatment protocols NCCN guidelines |
| gptkbp:regulatory_compliance |
breakthrough therapy designation
orphan drug designation |
| gptkbp:research_areas |
oncology
hematology |
| gptkbp:research_focus |
solid tumors
hematologic malignancies |
| gptkbp:safety_features |
combination therapy
monotherapy monitored in clinical trials |
| gptkbp:scholarships |
available for patients
|
| gptkbp:side_effect |
gptkb:fandom
fatigue nausea weight loss vomiting decreased appetite diarrhea constipation thrombocytopenia neuropathy |
| gptkbp:storage |
room temperature
protected from moisture |
| gptkbp:targets |
XP O1 protein
|
| gptkbp:type_of |
163521-12-8
|
| gptkbp:type_of_care |
important for efficacy
|